Subtype‐specific enhancer RNAs define transcriptional regulators and prognosis in breast cancers
Molecular Oncology · 2026-07 · 20 (7) · 1835-1856
DOI: 10.1002/1878-0261.70214 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 02.03.2026. Verfasst von Aamena Y Patel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular and Cellular Function, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, UK. Hauptthemen laut MEDLINE: Breast Neoplasms, Enhancer RNAs, Gene Expression Regulation, Neoplastic, Enhancer Elements, Genetic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK.
Abstract (Originalsprache)
Gene expression is tightly controlled by DNA elements called enhancers by associating with lineage‐specific transcription factors. These enhancers transcribe noncoding RNAs (called enhancer RNAs or eRNAs). eRNA expression is an early indicator of transcription factor activity and is associated with treatment response and survival in cancer patients. By analysing ~ 300 000 eRNA loci profiled using RNA‐sequencing data sets from 975 breast cancer patients using machine learning approaches, we categorised eRNAs specific to breast cancer molecular subtypes and survival. We associated these eRNAs with subtype‐specific mRNAs to define proximal co‐expressed regulatory eRNAs (ProxCReAm), which are enriched in pathways characteristic of their respective subtypes. Interestingly, cistrome and transcription factor motif analyses on these eRNAs highlighted involvement of diverse nuclear receptors (GR/AHR for luminal and GR/RAR for basal) and FOX factors in luminal regions. Moreover, luminal eRNAs were associated with better outcomes and Her2 eRNAs with worse outcomes in patients. Overall, we demonstrate that machine learning approaches performed on RNA‐seq data sets can classify functionally relevant subtype‐specific and prognostic eRNAs, which can identify critical gene pathways and transcription factor networks in breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Molecular and Cellular Function, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, UK.
- Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, UK.
- Bioinformatics Core Facility, Faculty of Biology, Medicine and Health, The University of Manchester, UK.
- Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, UK.
ORCID-Profile: Nathnael T Tuffa, Sankari Nagarajan
Förderung
- Cancer Research UK
Zitieren
APA
Patel, A. Y., Zarrineh, P., Tuffa, N. T., Sheth, J. H., Mohan, S., Iqbal, M., & Nagarajan, S. (2026). Subtype‐specific enhancer RNAs define transcriptional regulators and prognosis in breast cancers. Molecular Oncology, 20(7), 1835-1856. https://doi.org/10.1002/1878-0261.70214
Vancouver
Patel AY, Zarrineh P, Tuffa NT, Sheth JH, Mohan S, Iqbal M, et al. Subtype‐specific enhancer RNAs define transcriptional regulators and prognosis in breast cancers. Molecular Oncology. 2026;20(7):1835-1856. doi:10.1002/1878-0261.70214
BibTeX
@article{Patel2026,
author = {Patel, Aamena Y and Zarrineh, Peyman and Tuffa, Nathnael T and Sheth, Jigar H and Mohan, Sumitra and Iqbal, Mudassar and Nagarajan, Sankari},
title = {Subtype‐specific enhancer RNAs define transcriptional regulators and prognosis in breast cancers},
journal = {Molecular Oncology},
year = {2026},
volume = {20},
number = {7},
pages = {1835--1856},
doi = {10.1002/1878-0261.70214}
}
EUVIMED